Resources

8 Resources for

ruthanne williams roussel

Subscribe to this listing via:
RSS
Email

BNET Resources

Insider Buying Bodes Well For Orexigen: Ruthanne Williams Roussel submits: Domain Partners, Orexigen Therapeutic's founding VC, has upped its stake in Orexigen OREX through a series of recent share purchases on the open market, according to a series of Forms 4 filed with the SEC on November 24. The purchases total just over 400,000 shares...; Tags: Biotech, Healthcare, Ruthanne Williams Roussel, Orexigen Therapeutics Inc.; External links 2009-11-26
Four Weighty Reasons to Invest in Vivus: Ruthanne Williams Roussel submits: If Vivus's VVUS Qnexa proves as effective, well-tolerated and safe in pivotal Phase III trials as it so far has shown itself to be, then it has the potential to become a very successful obesity drug. by Ruthanne Williams Roussel; Tags: Healthcare, Ruthanne Williams Roussel, Arena Pharmaceuticals Inc., Vivus Inc.; External links 2009-03-11
Vivus: Still Undervalued: Ruthanne Williams Roussel submits: Vivus VVUS announced first quarter results and held a conference call, on which, uncharacteristically, there was only one question. Essentially, the story has not changed, which is good: Top-line data from the pivotal Phase III EQUIP and CONQUER trials is expected in 3Q09The first Phase...; Tags: Biotech, Healthcare, Ruthanne Williams Roussel, Vivus Inc.; External links 2009-05-12
Arena Patients Keep Weight Off, Bodes Well for Partnership: Ruthanne Williams Roussel submits: Arena's big news at the American Diabetes Association meeting last weekend was that the analysis of the two-year pivotal Phase III BLOOM study data showed that patients were keeping off the weight they were losing on lorcaserin. This of course is terrific and bodes...; Tags: Biotech, Ruthanne Williams Roussel, Arena Pharmaceuticals Inc.; External links 2009-06-10
Vivus: Rumors of Huge Revenue Drop Greatly Exaggerated: Ruthanne Williams Roussel submits: Vivus VVUS released a 10-Q for the second quarter Friday night, which caused some small excitement because of what appeared to be a huge year-over-year revenues drop but it should not have. VVUS hardly has any cash revenues. About $10 million of its...; Tags: Biotech, Healthcare, Ruthanne Williams Roussel, Vivus Inc.; External links 2009-08-05

Insider Selling at Vivus Not Yet Cause for Alarm: Ruthanne Williams Roussel submits: There’s a good argument to be made that insider buys are a stronger predictor of stock movements than insider sales. To boil it down, there are two basic reasons for this, which we can see by taking a look at Vivus Inc. VVUS as an...; Tags: Biotech, Healthcare, Ruthanne Williams Roussel, Vivus Inc.; External links 2009-09-15
Two Positive Notes for Arena Pharmaceuticals: Ruthanne Williams Roussel submits: Arena ARNA releases more top-line pivotal data on flagship obesity drug lorcaserin, this time from its BLOSSOM study Behavioral modification and Lorcaserin Second Study for Obesity Management Friday 9/18, before market open. Two things that could be great for ARNA: by Ruthanne Williams Roussel; Tags: Biotech, Ruthanne Williams Roussel, Arena Pharmaceuticals Inc.; External links 2009-09-18
What to Look for in Orexigen's Empatic Data Release: Ruthanne Williams Roussel submits: Heads up! Orexigen OREX is to release Phase IIB data for its second weight loss drug Wednesday morning before market open, then hold a conference call at 8:30 a.m. ET. Empatic weight loss results have been somewhat better than those for OREX’s other drug Contrave...; Tags: Biotech, Healthcare, Ruthanne Williams Roussel, Orexigen Therapeutics Inc.; External links 2009-09-30